Astal signs LoI with Immuna Therapeutics
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
Subscribe To Our Newsletter & Stay Updated